Showing 5331-5340 of 8820 results for "".
- Carpe: New Antiperspirant Twice As Effective As "Extra Strength"https://practicaldermatology.com/news/carpe-new-antiperspirant-twice-as-effective-as-extra-strength/2457623/Carpe’s newly launched underarm antiperspirant has been demonstrated to reduce sweat twice as effectively as the US legal standard for extra strength antiperspirants, the company says. While federal regulation requires that an extra strength antiperspirant demonstrate at least a 30% r
- AbbVie to Present New Data at 27th EADV Congresshttps://practicaldermatology.com/news/abbvie-to-present-new-data-at-27th-eadv-congress/2457625/AbbVie will present new data across investigational medicines and Humira® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September 12-1
- JW Pharmaceutical Signs Global Out-licensing Agreement for Atopic Dermatitis Drug Candidate with LEO Pharmahttps://practicaldermatology.com/news/jw-pharmaceutical-signs-global-out-licensing-agreement-for-atopic-dermatitis-drug-candidate-with-leo-pharma/2457626/JW Pharmaceutical and LEO Pharma A/S have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma will gain the exclusive rights to develop and commercialize JW1601 globally excluding Korea where JWP will maintain its exclusivity
- Compulink Launches Advantage SMART Practice Suite of AI Solutionshttps://practicaldermatology.com/news/compulink-launches-advantage-smart-practice-suite-of-ai-solutions/2457629/Compulink Healthcare Solutions rolled out new artificial intelligence (AI)-enabled features in a release its calling Advantage SMART Practice. Advantage uses AI technology and real-time data from the clinic to completely automate tasks such as billing, along with eliminating steps to improve pati
- New Skinder App May Help Med Students Spot Skin Cancerhttps://practicaldermatology.com/news/new-skinder-app-may-help-med-students-spot-skin-cancer/2457627/Skinder, a dermatologist-developed app, may help medical students learn to spot skin cancer. Skinder works like the matchmaking app Tinder. But instead of considering pictures of potential dates, swiping right if they’re attractive or left if they’re not, users consider high-r
- Psoriasis Myths, Stigmas Aboundhttps://practicaldermatology.com/news/myths-stigmas-about-psoriasis-abound/2457628/Stigmatizing views and myths about psoriasis are pervasive among the general population and medical students in the United States, according to multidisciplinary research from the Perelman School of Medicine at the University of Pennsylvania. The findings
- FDA Accepts Ortho Derm's Resubmission of NDA for Duobrii Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-ortho-derms-resubmission-of-nda-for-duobrii-lotion-for-plaque-psoriasis/2457630/The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application (NDA) for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis. The FDA accepted the application as a Class 2 resubmission, with a PDUFA action date of Feb. 15,
- General Medicine Update: Daily Aspirin May Not Work Wonders After Allhttps://practicaldermatology.com/news/general-medicine-update-daily-aspirin-may-not-work-wonders-after-all/2457633/It remains unclear whether daily aspirin lowers the risk of a cardiovascular event in individuals at moderate risk of a first heart attack or stroke, according to late-breaking results from the ARRIVE study presented at the European Society of Cardiology (ESC) Congress 2018 a
- FDA Nod for Ortho Derm's Acne Lotion Altrenohttps://practicaldermatology.com/news/fda-nod-for-ortho-derms-acne-lotion-altreno/2457635/The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Ortho Dermatologic’s Altreno (tretinoin 0.05%) lotion, indicated for the topical treatment of acne vulgaris in patients aged 9 and up. Altreno is expected to be
- Researchers Identify Cause of Aggressive SCCs in Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/researchers-identify-cause-of-aggressive-sccs-in-recessive-dystrophic-epidermolysis-bullosa/2457636/Immune system-related enzymes contribute significantly to the development of aggressive and fatal squamous cell carcinomas early in the life of individuals with recessive dystrophic epidermolysis bullosa (RDEB), an international team of scientists led by researchers at the Sidney Kimmel Canc